ILLUMINATION RADIATION TREATMENT OF SKIN CONDITIONS

A method and apparatus for the cosmetic treatment of a skin condition (particularly Acne Vulgaris). Illuminating radiation (including radiation of a predetermined wavelength) is directed toward a target zone in accordance with a predetermined delivery regime. A plurality of interactions are effected at the target zone including a reaction leading to at least partial disabling or eradication of the cause of the skin condition, and non-ablative heating of tissue stimulating an inflammatory response to a degree sufficient to effect collagen production. The two-fold interaction system effected by the illuminating radiation provides an extremely effective cosmetic effect.

Published:
— with international search report

before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the “Guidance Notes on Codes and Abbreviations” appearing at the beginning of each regular issue of the PCT Gazette.
ILLUMINATION RADIATION TREATMENT OF SKIN CONDITIONS

The present invention relates to cosmetic treatment of skin conditions such as, for example, Acne Vulgaris.

Acne Vulgaris is a condition of the sebaceous glands which affects 80% of individuals between the ages of 11 and 30. It is not confined to these age groups however and can affect all ages from neonates to the elderly. Factors which are considered of primary significance to the condition include an increase in the production of sebum, abnormal follicular keratinisation, the presence of Propionibacterium and subsequent inflammation.

Dependant on the size, content, and depth of the inflamed acne lesion, it is defined as a papule (less than 0.5cms in diameter), nodule (elevated solid lesion > than 0.5cms) pustule (a papule what contains purulent material) or a cyst (nodule that contains fluid or semisolid matter).

Hair follicles are minute passages in the skin, which allow hairs to grow and produce sebum secretions from sebaceous glands which are housed within the hair follicle. Due to increased androgen levels or an excessive reaction by the sebaceous glands to androgen production, the sebaceous glands enlarge resulting in increased secretion of sebum which along with the keratinisation process of the epithelial cells, clog the hair follicle. Initially these blockages are microscopic then develop into whiteheads or blackheads (Comedones). Congested follicles are an ideal medium for growth of bacteria. When sebum levels are
increased, the skin commensal propionibacterium ingest the
clogged sebum under the skin and chemicals are produced
which trigger the immune system to initiate the
inflammatory changes and erythematous macules associated
with Acne Vulgaris.

Inflammation is the body's response to invasion of
pathogens and the redness associated with the acne lesions
is the result of increased blood flow whereby the white
blood cells invade bacterial cells and damage tissue and
produce pus. Other fluids flood to the area and collect at
the site of the inflamed tissue.

The approaches which are currently used for tackling Acne
Vulgaris include Drug therapies (Systemic antibiotics,
cortisone injections, Dianette (women only contraceptive
pill, Roaccutane, Retinoids), PUVA (Psoralen and Ultra
Violet light, type A), UVB Phototherapy, Dermalux (a system
using a combination of red and blue light to treat acne),
Peeling agents, laser resurfacing, Dermabrasion and
Microdermabrasion.

Known apparatus for treating acne by irradiation are
disclosed, for example, in GB2356570, WO00/32272 and
US5549660. The present invention provides an improved
apparatus and method for the cosmetic treatment of skin
conditions (in particular acne).

According to the present invention, there is provided a
method for the cosmetic treatment of a skin condition
(particularly acne vulgaris), the method comprising
directing illuminating radiation, including illuminating radiation of a predetermined wavelength, toward a target zone of skin in accordance with predetermined delivery regime in order to effect at the target zone a plurality of interactions, including:

a) a reaction leading to at least partial disabling or eradication of the cause of the skin condition; and,

b) non-ablative heating of tissue stimulating an inflammatory response to a degree sufficient to effect collagen production.

The two-fold interaction system effected by the illuminating radiation provides an extremely effective cosmetic effect in that the interaction acts to clear up the skin condition and also stimulates the production of collagen to improve skin appearance (minimizing the appearance of scarring caused by the condition). A feature of the technique of the invention is that efficacy is achieved without the need of any other topically applied agent or any invasive or ablative procedure.

It is preferred that the interactions a) and b) defined above occur substantially contemporaneously.

The radiation is typically low intensity (avoiding ablation at or below the skin surface) and typically primarily of wavelength at or about the wavelength of yellow light (585nm) for reasons explained in detail later. Absorption
of light is through the dermal vasculature having no adverse effects on the epidermis.

Desirably, the reaction leading to at least partial removal or disabling of the cause of the skin condition is a photochemical reaction.

Beneficially, the heating interaction is a photothermal effect caused by selective absorption of the predetermined wavelength light, typically by a preselected chromophore.

For Acne Vulgaris the chromophore targeted to combat the propionibacterium is porphyrin in the connective tissue. This tissue bound photosensitiser when excited from light of a certain wavelength (approximately the wavelength of yellow light - 585nm), produces a photochemical reaction resulting in the production of singlet oxygen thereby destroying the bacterium.

Propionibacterium is averse to oxygen (anaerobic) and relies upon chemicals known as porphyrins in skin tissue. Porphyrin is usually innocuous in the absence of light. It is however photosensitive and when exposed to light of the required wavelength the photochemical reaction occurs. This results in a transition from the porphyrin’s ground state to a reactive triplet state. At this level, a reaction with molecular oxygen creates singlet oxygen. Through the medium of a suitable light source, to activate the porphyrins to produce singlet oxygen, the bacterium responsible for Acne Vulgaris can be cleared in a cosmetic, pain-free, non-invasive and efficient manner.
Vasodilation and hyperemia are integral parts of the inflammatory response, including response to infection. Therefore any inflammatory/infective focus contains a disproportionate concentration of red blood cells.

Porphyrin molecules are contained in the haem of haemoglobin so that any inflammatory or infective focus contains a concentration of natural porphyrin. Activation of this porphyrin using, for example, yellow (585nm) light releases substances which destroys adjacent toxins such as bacteria in acne.

Similarly, any acute inflammatory condition of skin such as rosacea will be helped although the exact toxin may be unknown.

Secondly, targeting the chromophore haemoglobin in the dermal vasculature plexus to create thermal injury stimulates the production of fibroblasts which is responsible for collagen production. The stimulated collagen produced is the skin’s natural filling material, which will cosmetically improve skin texture and appearance. Exposure to light (of a relevant selected wavelength) results in a selective, non-ablative photothermolysis effect in the target chromophore, that is oxyhaemoglobin. The interaction of the radiation (light) within the dermal vascular plexus induces an inflammatory/growth response. This results in the release of inflammatory mediators from the endothelial cells through the vessel walls and into the dermal interstitium where they stimulate fibroblast activity. Fibroblasts are
quiescent unless stimulated by inflammatory mediators. This creates a response by the fibroblasts to initiate tissue repair mechanisms which will in turn produce enhanced new collagen which is the skin's natural filling material and will improve skin texture and appearance.

The energy density of the energy delivered should be accurately controlled and monitored so as not to exceed a predetermined threshold level.

In order to stimulate fibroblast activity, the incident light must be absorbed in the microvasculature to release the necessary mediators which trigger fibroblast activity and hence collagen production.

Certain wavelengths of above, for example, 600nm (for example, 660nm - red) are not optimum for collagen stimulation as red light is not preferentially absorbed in haemoglobin/oxyhaemoglobin. An alternative option is to use two wavelengths, one with a high absorption in porphoryin, which has absorption peaks other than those in the yellow region, and at least one wavelength at yellow (570-590nm).

Where the skin condition is Acne Vulgaris it is therefore preferred that the wavelength of the illuminating radiation comprises a primary wavelength or narrow wavelength band substantially in the range 570-590nm.

Beneficially the radiation delivered is pulsed, the pulse duration preferably being less than the thermal relaxation
time of the target structure. This limits and controls the thermal damage done to the target structure, and controls the correct thermal and chemical response as required.

5 The photochemical interaction is typically dependent upon the number of incident photons, so the photons may be delivered in pulsed or continuous wave mode. However, for the stimulation of collagen, pulsed operation is preferred to ensure delivery of the required energy regime to cause the triggering of the release of inflammatory mediators.

The light (radiation) source may comprise laser sources (such as laser diodes) or light emitting diodes (LED's) if necessary with appropriate filter(s) to promote propagation of the required selected wavelength (or narrow wavelength band).

Also by using pulsed operation, light emitting devices (particularly LED's) may be driven harder to produce more light output. A typical LED can operate at a drive current of 50mA in continuous mode, whilst in pulsed operation, for short periods, the same diode can be pulsed at current of around 200mA. This pulsed operation may be between 1μs to 100msec (1μs to 5ms preferred). This will allow fewer diodes to be used for a given output power requirement or a larger area to be treated with same amount of diodes.

The target for the light source has to be a material that absorbs a specific wavelength and disregards other wavelengths (chromophore). In accordance with the invention, for Acne Vulgaris, the chromophores may be
porphyrin in skin tissue and oxyhaemoglobin in the dermal vasculature.

The preferred wavelength (or wavelengths) for this invention will depend upon the skin condition being treated but typically include a wavelength in the range of 400nm to 1500nm with a preferred range of 500-650nm.

The method according to the present invention is non-invasive and non-ablative and can readily be performed by non-medical personnel. The energy density of the radiation delivered to the skin surface is sufficient to effect the required heating of tissue stimulating an inflammatory response to a degree sufficient to effect collagen production without resulting in unwanted effects on the skin such as ablation and/or other damage. The energy density is therefore preferably substantially in the range of 0.5-5J/cm² (more preferably substantially in the range of 1.5-3.5J/cm²) via a pulsed or continuous wave. For pulsed operation the range is 10μs to 100ms with a preferred range of 50μs to 10ms.

According to a further aspect, the invention provides apparatus for cosmetic treatment of a skin condition (particularly Acne Vulgaris), the apparatus comprising illuminating radiation delivery means for delivering illuminating radiation to a target skin zone or structure.

The apparatus is preferably arranged to output radiation of a discrete wavelength (or narrow primary wavelength band) substantially in or about the range 400nm-1500nm, depending
upon the skin condition being treated. For treatment of acne vulgaris the preferred range is 500nm-650nm, most preferably 570nm-595nm.

The apparatus preferably delivers radiation at an energy density at the skin surface substantially in the range 0.5J/cm²-5J/cm², (more preferable substantially in the range 1.5-3.5J/cm²). The apparatus is preferably configured to inhibit output of energies substantially above this range. Desirably the apparatus is configured to permit variable selection of energy densities within the range.

The illuminating radiation may be pulsed or continuous wave. Pulsed energy may be preferred in order to avoid overheating of the target tissue structure (describe above) and produce the appropriate inflammatory response for collagen production. Pulse duration is preferably substantially in the range 10 microseconds - 100ms (preferably substantially in the range 50microseconds - 10ms).

According to a further aspect, there is provided a method for the manufacture of an agent for the treatment of a skin condition (particularly Acne Vulgaris), the agent comprising illuminating radiation active to effect at the target zone the following interactions:

a) a reaction leading to at least partial disabling of the cause of the skin condition; and,

b) non-ablative heating of tissue stimulating an
inflammatory response to a degree sufficient to
effect collagen production.

The invention has been primarily described in relation to
the cosmetic treatment of Acne Vulgaris. It will however
be appreciated that the two-fold nature of the action
described for the invention has potential with respect to
other skin conditions, including for example acute
inflammatory conditions such as Rosacea, depending upon the
selection of the appropriate chromophore/toxin.

The invention will now be further described in specific
embodiments, by way of example only and with reference to
the accompanying drawings, in which

Figure 1, is a schematic diagram of an embodiment of the
apparatus according to the invention;

The apparatus shown in Figure 1 comprises a laser radiation
delivery system 1. The laser radiation delivery system 1
comprises a flashlamp excited pumped dye laser including a
laser head 2, dye reservoir 4, and pump 6.

The system is controlled by a microprocessor controller 12,
which operates voltage control of a pulse forming network
14. The pulse forming network 14 includes a capacitor and
inductor network. A pulsed beam laser output from laser
head 2 is generated by a discharge pulse initiated by the
pulse forming network 14. A link 16 provides voltage
control and feedback between the microprocessor controller
12 and pulse forming network 14. Also included in system
1 is a flowmeter which regulates dye flow to the laser cavity in the laser head 2 and a cooling system 10 which cools the laser head 2 and dye reservoir 4. Temperature monitoring feedback is provided between the cooling system 10 and the controller 12 via link 18.

The radiation parameters may be selected to ensure that the total radiation energy density delivered per pulse falls substantially within the range 0.5J/cm² to 5J/cm². It is particularly important that the selected upper threshold value (5J/cm²) is not exceeded significantly as delivery of a higher energy densities of radiation per pulse can result in unwanted effects on the skin (such as ablation and/or other damage). The apparatus is therefore set to ensure an upper threshold permissible level of energy delivered per pulse to be at or below 5J/cm².

For the dye laser radiation delivery system 1 of Figure 1, the laser output energy in conjunction with the spot size determines the energy density delivered. The energy density of the radiation delivered to the skin is controlled by adjustment of the flashlamp output energy (which in turn controls the laser output energy). Accurate control is achieved by control of the dye circulation rate, the dye temperature and the flashlamp output energy. Dye circulation rate is important because repeated pulsing of the same volume of dye, without circulation, reduces the output energy of the laser head 2. Increasing or decreasing the dye temperature has an effect on the energy output of the laser head 2. The flashlamp output energy is controlled by varying the voltage with which the
capacitors in the pulse forming network 14 are charged; feedback of the capacitor voltage via link 16 is therefore important.

The energy density required will vary within the specified range from person to person, depending upon skin colour.

An alternative embodiment of an apparatus for performance of the present invention utilises an LED or semiconductor laser device to produce output radiation.

High intensity LED devices can provide wavelengths capable of producing the photochemical reaction of porphyrin hereinbefore described (approximately the wavelength of yellow light-585nm). A radiation delivery system using LED devices may include filters arranged to narrow the band of radiation passing from the LED to the target area of the skin. Where lasers are used, the output may be monochromatic. Alternatively, or in the case where LED's are used, the radiation delivered may be "effectively" monochromatic (for example by means of appropriate filtering) or of a relatively narrow band width (typically within a band width of 15nm of less).
CLAIMS:

1. A non-surgical method for the cosmetic treatment of a skin condition comprising directing illuminating radiation toward a target zone of skin in accordance with predetermined delivery regime in order to effect at the target zone a plurality of interactions, including:
   (a) a reaction leading to at least partial disabling or eradication of the cause of the skin condition; and
   (b) non-ablative heating of tissue stimulating an inflammatory response to a degree sufficient to effect collagen production.

2. A method according to claim 1, for the cosmetic treatment of Acne Vulgaris.

3. A method according to claim 1 or 2, wherein the illuminating radiation is of a predetermined wavelength.

4. A method according to any preceding claim, wherein the interactions (a) and (b) occur substantially contemporaneously.

5. A method according to any preceding claim, wherein the reaction leading to at least partial disabling or eradication of the cause of the skin condition is a photochemical reaction.
6. A method according to any preceding claim, wherein the illuminating radiation delivered is pulsed.

7. A method according to claim 6, wherein the pulse duration of the illuminating radiation is less than the thermal relaxation time of the target structure.

8. A method according to claim 6 or 7, wherein the pulse duration of the illuminating radiation is between 10μs to 100ms.

9. A method according to claim 8, wherein the pulse duration of the illuminating radiation is between 50μs to 10ms.

10. A method according to any preceding claim, wherein the wavelength of the illuminating radiation is in the range of 400nm to 1500nm.

11. A method according to claim 10, wherein the illuminating wavelength is in the range 500nm to 650nm.

12. A method according to claim 11, wherein the wavelength of the illuminating radiation comprises a primary wavelength or narrow wavelength band substantially in the range 570nm to 590nm.

13. A method according to any preceding claim, wherein the energy density of the illuminating radiation is in the range of 0.5J/cm² to 5J/cm².
14. A method according to claim 13, wherein the energy density of the illuminating radiation is in the range 1.5J/cm² to 3.5cm².

15. Apparatus for cosmetic treatment of a skin condition comprising illuminating radiation delivery means for delivering illuminating radiation to a target skin zone or structure.

16. Apparatus according to claim 15, for cosmetic treatment of Acne Vulgaris.

17. Apparatus according to claim 15 or 16, arranged to output radiation of a discrete wavelength or narrow primary wavelength band substantially in or about the range 400nm to 1500nm.

18. Apparatus according to claim 17, arranged to output radiation of a discrete wavelength or narrow primary wavelength band substantially in or about the range 500nm to 650nm.

19. Apparatus according to claim 18, arranged to output radiation of a discrete wavelength or narrow primary wavelength band substantially in or about the range 570nm to 595nm.

20. Apparatus according to any of claims 15 to 19, arranged to deliver radiation at an energy density at the skin surface substantially in the range 0.5J/cm² to 5J/cm².
21. Apparatus according to claim 20, configured to inhibit output of energies substantially above 5J/cm².

22. Apparatus according to claim 20 or 21, configured to permit variable selection of energy densities within the range 0.5J/cm² to 5J/cm².

23. Apparatus according to any preceding claim, arranged to deliver radiation at an energy density at the skin surface substantially in the range 1.5J/cm² to 3.5J/cm².

24. Apparatus according to claim 23, configured to inhibit output of energy substantially above 3.5J/cm².

25. Apparatus according to claim 23 or 24, configured to permit variable selection of energy densities within the range 1.5J/cm² to 3.5J/cm².

26. Apparatus according to any of claims 15 to 25, arranged to deliver illuminating radiation in a pulsed regime.

27. Apparatus according to claim 26, wherein the pulse duration of the illuminating radiation is substantially in the range 10μs to 100ms.

28. Apparatus according to claim 27, wherein the pulse duration of the illuminating radiation is substantially in the range 50μs to 10ms.
29. A method or apparatus for the manufacture of an agent for the treatment of a skin condition, the agent comprising illuminating radiation active to effect at the target zone the following interactions:

(a) a reaction leading to at least partial disabling of the cause of the skin condition; and

(b) non-ablative heating of tissue stimulating an inflammatory response to a degree sufficient to effect collagen production.

30. A method according to claim 29, for the treatment of Acne Vulgaris.
Continuation of Box I.1

Claims Nos.: 1-14

Rule 39.I(iv) PCT - Method for treatment of the human or animal body by therapy. The cosmetic effect is to be seen as a bonus effect. In the first instance, the method is therapeutical because a skin disease (i.e. acne vulgaris which is an inflammatory infection by bacteria) is treated.

Continuation of Box I.2

Claims Nos.: 29 30

In claim 29 an apparatus or method for the manufacture of an agent is claimed. The agent is only characterised by "illuminating radiation". Radiation, however, is not a product that can be manufactured, but merely an effect. Therefore, it is not clear which technical features are referred to in claim 29 and hence, no meaningful search is possible for this claim (Articles 6 and 17.2 b PCT).

The applicant’s attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.
# INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

| IPC       | A61N5/06 |

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

| IPC       | A61N A61B |

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P,X</td>
<td>WO 00 74782 A (BJERRING PETER; CLEMENT ROBERT MARC (GB); KIERNAN MICHAEL NOEL (GB) 14 December 2000 (2000-12-14) page 3, line 5 - line 9 page 4, line 20 - line 25 page 8, line 21 - line 29</td>
<td>15-28</td>
</tr>
<tr>
<td>X</td>
<td>WO 99 58195 A (AZAR ZION; DELIGHT TECHNOLOGIES LTD (IL)) 18 November 1999 (1999-11-18) page 9, line 5 - line 11 page 14, line 16 - line 21</td>
<td>15-28</td>
</tr>
<tr>
<td>X</td>
<td>EP 0 765 674 A (ESC MEDICAL SYSTEMS LTD) 2 April 1997 (1997-04-02) column 1, line 32 - line 44</td>
<td>15-18, 26-28</td>
</tr>
</tbody>
</table>

**X** Further documents are listed in the continuation of box C.  
**X** Patent family members are listed in annex.

* Special categories of cited documents:
  
  *A* document defining the general state of the art which is not considered to be of particular relevance  
  *E* earlier document but published on or after the international filing date  
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
  *O* document relating to an oral disclosure, use, exhibition or other means  
  *P* document published prior to the international filing date but later than the priority date claimed  
  *I* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
  *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
  *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
  *G* document member of the same patent family

Date of the actual completion of the international search  
28 February 2002

Date of mailing of the international search report  
06/03/2002

Name and mailing address of the ISA  
European Patent Office, P.B. 5018 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 540-2040, Tx. 31 651 epo nl  
Fax. (+31-70) 340-3016

Authorized officer  
Petter, E

Form PCT/GB/210 (second sheet) (July 1992)
### INTERNATIONAL SEARCH REPORT

#### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
| X        | US 5 464 436 A (SMITH CHADWICK F)  
7 November 1995 (1995-11-07)  
column 4, line 66 - column 5, line 1  
column 4, line 23 - line 36  
column 10, line 10 - line 12  
column 11, line 18 - line 25 | 15-17, 20-26 |
| X        | DE 41 43 168 A (REHA TEC VERTRIEBSGES FUR MEDI) 1 July 1993 (1993-07-01)  
column 3, line 4 - line 6; claim 3 | 15-19, 26 |
| X        | WO 96 33773 A (OLAVESEN BROAD MARIANNE; OLAVESEN LIMITED (GB))  
31 October 1996 (1996-10-31)  
page 3, line 1 - line 2; claims 1,4 | 15-19 |
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 0074782 A</td>
<td>14-12-2000</td>
<td>AU 5094600 A</td>
<td>28-12-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0074782 A1</td>
<td>14-12-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20015809 A</td>
<td>17-01-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 3440899 A</td>
<td>29-11-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9910373 A</td>
<td>30-01-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1300227 T</td>
<td>20-06-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9958195 A1</td>
<td>18-11-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2002019625 A1</td>
<td>14-02-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 705382 B2</td>
<td>20-05-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6446596 A</td>
<td>10-04-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2185197 A1</td>
<td>29-03-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0765674 A2</td>
<td>02-04-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 9103508 A</td>
<td>22-04-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9529736 A1</td>
<td>09-11-1995</td>
</tr>
<tr>
<td>DE 4143168 A</td>
<td>01-07-1993</td>
<td>DE 4143168 A1</td>
<td>01-07-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9633773 A2</td>
<td>31-10-1996</td>
</tr>
</tbody>
</table>